1. Transdermal Fentanyl in Opioid-Naive Cancer Pain Patients
Ans P.E Vielvoye-Kerkmeer, MD, PhD, Carlien Mattern, MD, Martin P Uitendaal, PhD 
Journal of Pain and Symptom Management 
Volume 19, Issue 3, Pages (March 2000)
DOI: /S (99)

2. Fig. 1
Trial design
Journal of Pain and Symptom Management  , DOI: ( /S (99) )

3. Fig. 2
Number of patients during the course of the study (with reason for dropping out). The AEs that were reason for dropping out are numbered: AE1 hallucinations, nausea and vomiting (possibly due to fentanyl administration); AE2 sleepiness (possibly due to fentanyl administration) and fever (unlikely due to fentanyl administration); AE3 nausea (possibly due to fentanyl administration); AE4 skin irritation (due to the fentanyl patch)
Journal of Pain and Symptom Management  , DOI: ( /S (99) )

4. Fig. 3
Number of patients receiving the various doses of fentanyl (in μg/hr) during the course of this study
Journal of Pain and Symptom Management  , DOI: ( /S (99) )

5. Fig. 4 Averge pain score in the morning (patients' diaries)
Journal of Pain and Symptom Management  , DOI: ( /S (99) )

6. Fig. 5 Average number of morphine (5 mg) capsules per day
Journal of Pain and Symptom Management  , DOI: ( /S (99) )

7. Fig. 6
Overall opinion of the patients about the treatment at different time points and at the end point for each individual patient in opioid-naive (top) and codeine-using (bottom) patients. The data of day 0 refer to the previous treatment. No patient received adequate pain control at day 0, which is in agreement with the inclusion criteria
Journal of Pain and Symptom Management  , DOI: ( /S (99) )